Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. (Q47917346)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 October 2009

Language	Label	Description	Also known as
English	Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.	scientific article published on 24 October 2009

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Plasmodium falciparum

1 reference

based on heuristic

inferred from title

Elke S Bergmann-Leitner

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Marie-Claude Dubois

16

object named as

M C Dubois

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

11

object named as

E Angov

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

D. Gray Heppner

19

object named as

D G Heppner

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

S Pichyangkul

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

P Tongtawe

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

U Kum-Arb

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

K Yongvanitchit

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

M Gettayacamin

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

M R Hollingdale

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

A Limsalakpetch

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

V A Stewart

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

D E Lanar

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

S Dutta

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

L A Ware

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

B House

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

G Voss

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

J D Cohen

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

M M Fukuda

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

R S Miller

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

language of work or name

0 references

publication date

24 October 2009

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

number of pages

11

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

28

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

452-462

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

The nature and consequences of intra- and inter-vaccine interference

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Enhanced protection against malaria by a chimeric merozoite surface protein vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Development, characterization and immunogenicity of a multi-stage, multi-valent Plasmodium falciparum vaccine antigen (FALVAC-1A) expressed in Escherichia coli.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Reduced immunogenicity of DNA vaccine plasmids in mixtures

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Special Report: The 1996 Guide for the Care and Use of Laboratory Animals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Profiling the antibody immune response against blood stage malaria vaccine candidates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Proteolytic processing and primary structure of Plasmodium falciparum apical membrane antigen-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Towards a blood-stage vaccine for malaria: are we following all the leads?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Immune responses to asexual blood-stages of malaria parasites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Deletion of Plasmodium berghei-specific CD4+ T cells adoptively transferred into recipient mice after challenge with homologous parasite

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Apoptotic deletion of Th cells specific for the 19-kDa carboxyl-terminal fragment of merozoite surface protein 1 during malaria infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

The mechanism and significance of deletion of parasite-specific CD4(+) T cells in malaria infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Dendritic cells, pro-inflammatory responses, and antigen presentation in a rodent malaria infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Pathology of Plasmodium chabaudi chabaudi infection and mortality in interleukin-10-deficient mice are ameliorated by anti-tumor necrosis factor alpha and exacerbated by anti-transforming growth factor beta antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Activation of a subset of human NK cells upon contact with Plasmodium falciparum-infected erythrocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

The war between the malaria parasite and the immune system: immunity, immunoregulation and immunopathology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

The immunogenicity and reactogenicity of DTPw-HBV/Hib 2.5 combination vaccine: results from four phase III multicenter trials across three continents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Immunogenicity of a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Dimorphic Plasmodium falciparum merozoite surface protein-1 epitopes turn off memory T cells and interfere with T cell priming.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibody-independent immunity to reinfection malaria in B-cell-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.10.022

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47917346&oldid=1775328998"